Discover Oncology, Год журнала: 2025, Номер 16(1)
Опубликована: Апрель 29, 2025
Язык: Английский
BMC Cancer, Год журнала: 2025, Номер 25(1)
Опубликована: Янв. 8, 2025
Recent advancements in contemporary therapeutic approaches have increased the survival rates of lung cancer patients; however, long-term benefits remain constrained, underscoring pressing need for novel biomarkers. Surfactant-associated 3 (SFTA3), a long non-coding RNA predominantly expressed normal epithelial cells, plays crucial role development. Nevertheless, its function adenocarcinoma (LUAD) remains inadequately understood. Single-cell sequencing data were utilized to identify cell-intrinsic gene signatures associated with progression LUAD, and their roles LUAD comprehensively analyzed. Serum samples collected quantify expression levels SFTA3 patients. Furthermore, series biological experiments, including cell viability assays, scratch wound healing colony formation conducted demonstrate tumor-suppressive effects SFTA3. was performed elucidate molecular mechanisms underlying cells. We constructed prognostic model comprising eight genes: ALDOA, ATP5MD, SERPINH1, SFTA3, SLK, U2SURP, SCGB1A1, SCGB1A3. The effectively stratified patients into high- low-risk categories, revealing that experienced superior clinical outcomes, exhibited an immunologically hot tumor microenvironment (TME), had greater probability responding immunotherapy. In contrast, high-risk group cold TME may benefit more from chemotherapy. our study revealed progressive decrease cells correlated advancement. Notably, serum significantly decreased suggesting potential utility liquid biopsy diagnosis. Additionally, knockdown enhances proliferation migration whereas overexpression inhibits these phenotypes. epithelial-mesenchymal transition pathway enriched following silencing, impact by modulating this process. also identified key transcription factors epigenetic implicated downregulation LUAD. developed robust as biomarker applications diagnosis, prognosis, personalized treatment findings offer new insights tumorigenesis immune evasion.
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2025, Номер 17(5), С. 788 - 788
Опубликована: Фев. 25, 2025
Ovarian cancer is the fifth leading cause of cancer-related death among women, which one most common gynecological cancers worldwide. Although several cytoreductive surgeries and chemotherapies have been attempted to address ovarian cancer, disease still shows poor prognosis survival rates due prevalent metastasis. Peritoneal metastasis recognized as primary route metastatic progression in cancer. It causes severe symptoms patients, but it generally difficult detect at an early stage. Current anti-cancer therapy insufficient completely treat its high recurrence resistance. Therefore, developing strategies for treating requires a deeper understanding tumor microenvironment (TME) identification effective therapeutic targets through precision oncology. Given that various signaling pathways, including TGF-β, NF-κB, PI3K/AKT/mTOR influence progression, their activity significance can vary depending on type. In these pathways are particularly important, they not only drive also impact TME, contributes potential. The TME plays critical role driving features altered immunologic interactions. Recent advances focused targeting distinct improve treatment outcomes. Deciphering complex interaction between immune populations contributing provides opportunity enhance efficacy. Hereby, this review highlights mechanisms immunological interactions understand improved immunotherapy against
Язык: Английский
Процитировано
0
Neoplasia, Год журнала: 2025, Номер 64, С. 101164 - 101164
Опубликована: Апрель 4, 2025
Язык: Английский
Процитировано
0
Discover Nano, Год журнала: 2025, Номер 20(1)
Опубликована: Апрель 24, 2025
Cancer treatments often exploit oxidative stress to selectively kill tumour cells by disrupting their lipid peroxidation membranes and inhibiting antioxidant enzymes. However, plays a dual role in cancer progression, acting as both promoter suppressor. Balancing through therapy remains challenge, excessive activity may compromise the efficacy of chemotherapy radiotherapy. This review explores antioxidants mitigating while maintaining treatment efficacy. It highlights recent advancements nanotechnology-based targeted delivery optimize therapeutic outcomes. A comprehensive literature was conducted using reputable databases, including PubMed, Scopus, Web Science, ScienceDirect. The search focused on publications from past five years (2020-2025), supplemented relevant studies earlier years. Keywords such "antioxidants," "lipid peroxidation," "nanotechnology therapy," "oxidative stress" were utilized. Relevant articles critically analysed, graphical illustrations created. Emerging evidence suggests that nanoparticles, liposomes, polymeric metal-organic frameworks, others, can effectively encapsulate control release minimizing systemic toxicity. Stimuli-responsive carriers with tumour-specific targeting mechanisms further enhance delivery. Studies indicate these strategies help preserve normal cells, mitigate stress-related damage, improve challenges bioavailability, stability, potential interactions standard therapies remain. Integrating nanotechnology antioxidant-based interventions presents promising approach for optimizing therapy. Future research should focus refining modulation strategies, assessing profiles during treatment, employing biomarkers determine optimal dosing. balanced use adverse effects.
Язык: Английский
Процитировано
0
Discover Oncology, Год журнала: 2025, Номер 16(1)
Опубликована: Апрель 29, 2025
Язык: Английский
Процитировано
0